Related Tags >> FDA Rituxan Roche Phase II

Rheumatoid Arthritis News

Most Popular Rheumatoid Arthritis Story

Ocrelizumab - Top 10 Phase III Failures

October 21, 2010 — 6:36am ET | By John Carroll

The drug: OcrelizumabThe disease: Rheumatoid arthritisThe company: Roche At the end of 2009, ocrelizumab looked every inch of a blockbuster for rheumatoid arthritis. The drug hit its primary endpoint Read more...

Rheumatoid Arthritis Press Releases

HealthyWomen and UCB, Inc. Host "Women Succeeding with Chronic Conditions" Health Pavilion at NBC4 Health and Fitness Expo
RainDance Technologies Teams with Hospital Saint-Louis and BGI to Confirm Mutations Associated with Rheumatoid Arthritis
Lycera Achieves First Milestone in Merck Research Collaboration
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modula
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST

Latest Headlines

Vertex tracks encouraging IIa data for JAK3 rheumatoid arthritis drug
September 6, 2011
Pfizer's potential offload of biz units could aid R&D prospects
July 8, 2011
Alder lands $15M milestone from blockbuster BMS antibody deal
June 20, 2011
Germany's 4SC misses mark in key RA drug trial, CEO keeps faith
June 9, 2011
German contender chases Pfizer in oral RA drug pursuit
May 27, 2011
Pfizer investigator questions cause of deaths in tofacitinib trial
May 25, 2011
Pfizer lays out slate of Ph3 successes for its crucial RA program
April 28, 2011
Pfizer scrambles to reassure investors on RA drug deaths
April 25, 2011
Galapagos ditches its experimental arthritis drug
April 15, 2011
Pfizer's potential blockbuster RA drug reports Phase III success
April 15, 2011
Pfizer's blockbuster RA hopeful clears a Ph3 hurdle
March 4, 2011
Immune cells' "master switch" offers blockbuster drug target
January 18, 2011
Pfizer's ($PFE) RA pill tasocitinib posts blockbuster PhIII results
November 8, 2010
Ocrelizumab - Top 10 Phase III Failures
October 21, 2010
AZ/Rigel RA drug hits PhIIb paydirt
September 23, 2010
Trubion slumps after Pfizer kills lead RA drug program
June 15, 2010
FDA approves Roche's Actemra for RA
January 11, 2010
Lilly nabs rights to Incyte's RA drug for $755M
December 21, 2009
Roche's RA drug posts blockbuster results in Phase III
December 11, 2009
Array BioPharma shares down on mid-stage RA trial failure
September 4, 2009

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events